久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國ImmunoCellular Therapeutics
IMUC 是一家總部位于洛杉磯的臨床階段公司，致力于開發(fā)免疫療法來治療腦癌和其它癌癥。該公司的先導(dǎo)候選產(chǎn)品 ICT-107 最近進入II期試驗，ICT-107 是一種基于樹突狀細胞的疫苗，該疫苗以多個腫瘤相關(guān)抗原為靶向，用于治療新診斷出的膠質(zhì)母細胞瘤。

Our mission is to improve cancer treatment and diagnosis through the discovery and development of new immune-based products. Designed to harness both arms of the native immune system, our pipeline includes both active immunotherapies and patented monoclonal antibodies (mABs). Our active immunotherapies target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our most advanced clinical programs are in glioblastoma multiforme (GBM), but our technologies have potential applications in many cancers with high unmet medical need, including pancreatic, ovarian, colon, small-cell lung, and multiple myeloma.

Our lead product candidate is ICT-107, a personalized, dendritic cell-based vaccine for the treatment of GBM. We intend to initiate a Phase II study of ICT-107 later this year following the strong results of a Phase I study in which it significantly prolonged survival with minimal side effects. We also intend to file an IND for ICT-121, our peptide-based “off-the-shelf” vaccine for the treatment of GBM.

Our strategy is to become the first company focused primarily on the development of cancer stem cell therapeutics, while working with partners to develop and commercialize our broadly applicable monoclonal antibodies. We have strong intellectual property surrounding our monoclonal antibodies, which were designed with our proprietary discovery technology. We also have an exclusive worldwide licensing agreement with Cedars-Sinai Medical Center for our immunotherapy and cancer stem-cell technologies.
?